Compare SKYH & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYH | FULC |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.2M | 285.4M |
| IPO Year | 2020 | 2019 |
| Metric | SKYH | FULC |
|---|---|---|
| Price | $10.38 | $3.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $13.13 | ★ $16.38 |
| AVG Volume (30 Days) | 183.4K | ★ 1.7M |
| Earning Date | 05-12-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,540,000.00 | N/A |
| Revenue This Year | $78.89 | N/A |
| Revenue Next Year | $73.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.57 | N/A |
| 52 Week Low | $8.22 | $2.83 |
| 52 Week High | $11.70 | $15.74 |
| Indicator | SKYH | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 51.36 |
| Support Level | $10.25 | $3.44 |
| Resistance Level | $10.41 | $3.96 |
| Average True Range (ATR) | 0.41 | 0.12 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 20.76 | 64.62 |
Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.